politics
CEO of Dr Reddy's warns U.S. generic drug prices may rise due to tariffs
24 Temmuz 2026CNBC
- The CEO of Dr Reddy's, a prominent Indian pharmaceutical firm, has raised concerns about the impact of proposed tariffs on generic drugs by the Trump administration. These tariffs are expected to lead to higher prices for patients who rely on affordable medication.
- The warning highlights the potential consequences of trade policies on healthcare costs in the U.S.
- has been increasingly scrutinizing its trade relationships, particularly with countries like India, which is a major supplier of generic medications. The potential tariffs are part of a broader strategy to address trade imbalances but could have unintended consequences for American consumers.
- The proposed tariffs on generic drugs could significantly disrupt the pharmaceutical market, particularly affecting low-income patients who depend on these medications for their health. As generic drugs often serve as the more affordable alternative to brand-name prescriptions, any increase in their prices could exa…
NewsAI özeti
This article reflects the opinions of the CEO of Dr Reddy's and does not necessarily represent the views of all stakeholders in the pharmaceutical industry.
Orijinal Kaynak
Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.
Kaynağı Görüntüleİlgili Haberler
Tümünü Gör
NewsAI Mobil Uygulamaları
Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.